Gilead Sciences agreed to acquire Arcellx in a deal valued at about $7.8 billion to secure full control of anito‑cel, a BCMA‑directed CAR‑T therapy for multiple myeloma. The acquisition converts an existing Kite–Arcellx collaboration into sole ownership for Gilead and removes future profit‑share and milestone splits. Company filings and press statements show Gilead is positioning anito‑cel as a potential competitor to J&J/Legend’s Carvykti, with the target PDUFA review date cited later this year. The deal includes a cash upfront payment and contingent value elements tied to future commercial milestones. Investors reacted strongly to the announcement, sending Arcellx shares sharply higher while larger biotech indices moved modestly.